Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy

SIMPLE SUMMARY: Anti-CTLA-4 and anti-PD-1 immune checkpoints inhibitors (ICI) have revolutionized the treatment of metastatic melanoma patients, leading to durable responses. However, some patients still not respond to this clinically used immunotherapies and there is a lack of biomarkers leading to...

Descripción completa

Detalles Bibliográficos
Autores principales: Rethacker, Louise, Roelens, Marie, Bejar, Claudia, Maubec, Eve, Moins-Teisserenc, Hélène, Caignard, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004602/
https://www.ncbi.nlm.nih.gov/pubmed/33810032
http://dx.doi.org/10.3390/cancers13061446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004602/
https://www.ncbi.nlm.nih.gov/pubmed/33810032
http://dx.doi.org/10.3390/cancers13061446

Ejemplares similares